What are you shorts going to do when the BLA is filed? You act as if this is all a make believe play. Regardless of it happening next week or in the coming weeks it’s going to happen. That’s not rocket science just fact. Science is solid, data will continue to stack, non dilutive deal will be signed, BTD will come through in the coming months, China and Taiwan deal is on the table, and that’s the short list...no pun intended. Are you guys ignorant enough to think none of this will transpire. It’s clear your going to have to start figuring out where next to take your copy and paste surface story.
When a company like CytoDyn comes out with excellent news day after day and has the potential to be the next best thing in coronavirus treatments in the near term and no one pays attention, blame is going to fall squarely on the SHORTS. It was evident last Friday at the height of coronavirus fears when the company announced an investor conference call update headline with a seemingly endless supply of positive news forthcoming. After the announcement hit the wire investors started piling on to buy it then the rally ran into a brick wall and started going lower again. The headline highlighted the Phase 2 trial for COVID-19, BLA update, BTD, Basket trial filing, and licensing opportunities. It was clear that this was going to be a very positive update. The conference call delivered but the reaction is still tepid as the bulls and the bears are duking it out. Right now the shorts can still cling to the hope that CytoDyn hasn’t filed their BLA yet and will not complete the filing until the end of March, but investors are also to blame or asleep at the switch here because in by the beginning of the month the FDA could come through with a Breakthrough Therapy Designation (BTD) approval worth billions of dollars.
